

RICE UNIVERSITY

**Using Multiple Imputation, Survival Analysis,
And Propensity Score Analysis In Cancer Data
With Missingness**

by

Nathan Karmazin Berliner

A THESIS SUBMITTED
IN PARTIAL FULFILLMENT OF THE
REQUIREMENTS FOR THE DEGREE
Master of Arts Statistics

APPROVED, THESIS COMMITTEE:

Rudy Guerra, Committee Chair
Professor of Statistics

Kenneth Hess, Thesis Director
Professor, MD Anderson Cancer Center

Yu Shen
Professor, MD Anderson Cancer Center

Marina Vannucci
Professor of Statistics

David Scott
Professor of Statistics

Houston, Texas

December, 2015

ABSTRACT

Using Multiple Imputation, Survival Analysis, And Propensity Score Analysis In Cancer Data With Missingness

by

Nathan Karmazin Berliner

In this thesis, multiple imputation, survival analysis, and propensity score analysis are combined in order to answer questions about cancer data with moderate missingness. While each of these fields have been studied individually, there has been little work and analysis on using the three in trio. Starting with an incomplete dataset, the goal is to impute the missing data, run survival analysis on each of the imputed datasets, and then do propensity score analysis to observe causal effects. Along the way, many theoretical and analytical decisions are made. I explain why each decision is made, and offer ample evidence for the other choices such that the interested reader may implement the methods if they so choose. I apply the methodology to a cancer survival dataset in a case study, but the methods used are general, and could be adapted for any type of data.

Contents

Abstract	ii
List of Illustrations	v
List of Tables	vi
1 Introduction and Background Information	1
1.1 Motivation	1
1.2 Imputation	2
1.3 Survival	5
1.4 Causal Analysis	9
2 Methods	14
2.1 Multiple Imputation	14
2.1.1 Selecting the MI scheme	15
2.1.2 Setting and checking the model	20
2.1.3 Combining the MI estimates	22
2.2 Survival analysis	25
2.2.1 Kaplan-Meier Survival Curve	25
2.2.2 Median Survival Time	26
2.2.3 Log Rank Test	27
2.2.4 Cox Proportional Hazards Model	28
2.3 Propensity Score Analysis	30
3 Application	34
3.1 Data Explanation	34

3.2	Imputation	37
3.3	Survival Analysis	43
3.4	Causal Analysis	51
4	Discussion	55
5	Conclusion	59
A	Appendix	60
A.1	Missing data mechanisms	60
A.2	Cancer and Treatment Overview	63
	Bibliography	65

Illustrations

1.1	Visualization of MI data	5
2.1	Normal JM imputation pseudocode	16
2.2	MICE FCS imputation pseudocode	18
3.1	Visualization of missingness in the cancer dataset	37
3.2	Selected plots of continuous variable imputation mean and standard deviation by iteration	42
3.3	Selected plots of binarys variable imputation mean and standard deviation by iteration	43
3.4	Landmarked Kaplan-Meier curves for chemotherapeutic drugs, AC and MI data	46
3.5	Landmarked Kaplan-Meier curves for HER2 drugs, AC and MI data .	47
3.6	AC Schoenfeld residuals over time	49
3.7	MI Schoenfeld residuals over time	51

Tables

3.1	Data Categories and Examples	35
3.2	Table of important covariates to be used in the analysis	36
3.3	Percent observed and influx and outflux of the worst predictors. Ki67, brca, and p53 are cancer markers, ECOG and GPA are performance scores	40
3.4	Characteristics of available case data versus MI data	44
3.5	Chemo log rank tests	48
3.6	HER2 log rank tests	48
3.7	AC and MI baseline Cox model	50
3.8	AC and MI Cox model with chemo treatment	52
3.9	AC and MI Cox model with HER2 directed treatment, on HER2+ subjects	53

Chapter 1

Introduction and Background Information

1.1 Motivation

The motivation of this thesis is to show the methodology that can be used both by applied researchers and clinicians to draw meaningful survival and causal inference from imputed data. While all three fields (imputation, survival, causal) are well studied, their interaction is not. I want the methods to be easy enough to describe to someone with a limited statistical background, but meaningful and valid so that the results obtained can be used in publication. The desire to have it this way stems from working on a related project with both statisticians and clinicians. While this thesis is motivated by cancer data, I believe that the methods used in this thesis are general enough to be applied to other types of data and situations.

Missing data is a major problem in both statistics and medicine; however, it has not received attention proportional to its need. Survival analysis is well studied, but is relatively complete, so little new research comes out of this field. Propensity score analysis will help us determine causal relationships when we don't have a randomized controlled experiment. As one could imagine, all three of these fields are important to the applied statistician, as they will come across at least one at some point in their career. The goal of this thesis is to demonstrate how to use all three in trio, a topic that has only received little interest in the literature. I will explain each of these three disciplines in detail before we dive into combining them.

1.2 Imputation

In an ideal world, we would have complete data with no missingness, however this is rarely ever the case. Imputation (specifically multiple imputation) is a way to “fill in missing data” with plausible values, and it forms the base of this thesis. All of the other analyses that will be used will follow from it, thus we need a solid understanding of it before we may proceed. Imputation itself has been around since the 1930’s [1], but multiple imputation is a recent development, proposed in the 1970’s and formalized in 1987 by Donald Rubin [2]. To understand the use and importance of multiple imputation, we need to understand the problem of missing data, and the previous attempts to deal with it.

At first, statisticians paid no attention to missing data, and happily discarded records from their data that were incomplete. This procedure is known as complete case (CC) analysis. There are many problems with this paradigm. To begin with, you will lose a lot of statistical power when, because you are throwing away records and thus decreasing your sample size. In addition, this can be costly to the researcher. If it costs a set amount to collect a single record, and you don’t use this record, you are wasting money. As well, in some rare cases, incomplete data might be the only type we can get (e.g. if we have a machine that analyzes a blood sample chemical level, but can’t detect it if the level is too high or low). Lastly, and most importantly, we will be biasing our estimates if we discard them. For example, suppose we have a random sample of people and are testing a drugs efficacy, and want to run a regression on some collected covariates. If men are known to not want to give all of their information, in the analysis, we will need to discard the male samples because they are incomplete, leaving us only with women. Thus, we no longer have a random sample, and will get biased results because we have knowingly thrown away half of our data which we

know to be different [1].

A slight improvement on this is called available case (AC) analysis. In this setting, a record is used in the analysis if it has all of the needed information for that analysis. So, a record could have missingness, but if the covariate with missingness is never used in the analysis, it will not be discarded. This paradigm is the standard analysis type for most statistical packages. It is better than complete case analysis, but is still flawed. We are still throwing away valuable data as we were with complete case analysis, although likely not as much. Available case analysis will still lead to bias in the same way that complete case did too. As well, new complications arise in available case analysis, namely that nonsensical situations like correlations outside of ± 1 , and inconsistent sample sizes for different analyses can arise.

The next wave of statisticians in the early 20th century wanted to improve upon available case analysis, so they developed what we now call today imputation. Their specific incarnation was called single imputation, and their goal was to fill in missing values with a single plausible replacement value. A single method (such as regression, taking the mean, resampling) is used one time to impute or fill in the missing value. While this is a little better than complete case analysis, it still has many drawbacks. Asserting that a single value is the true value is unjustified. There is always some amount of error and uncertainty involved, and we can in no way be 100% confident that our imputed value is correct. Furthermore, if I impute one value and you impute another, we may get completely different results from analysis on the data. This is obviously not a desirable trait. In addition, imputing one time and calling it your true data will artificially increase your sample size. You are in effect treating the imputed values as if they were real, inflating your sample size with data that was not actually observed. This will give you unjustified statistical power and accuracy. While single

imputation certainly has its drawbacks, the idea of actually trying to fill in the data is an important one, and multiple imputation fills in the gaps that single imputation is not able to cover.

Multiple imputation (MI) began in the 1970's, but it wasn't until 1987 when Donald Rubin formalized multiple imputation methodology in his seminal book *Multiple Imputation for Nonresponse in Surveys* did it start to gain acceptance [2]. The central idea is to frame the problem in a Bayesian framework, and produce $m \geq 2$ values to substitute in for each missing value, drawing these values from the missing covariates posterior distribution. Using these substitute values (m values), we can think of the data now as being m datasets, each dataset containing the observed data, and one value for each piece of missing data.

An example will make the MI process clear. Suppose that we had a dataset of age, weight, and height. We want to regress age on weight but we have missingness. First, we will impute our data (figure 1.1, the first two columns). Once we have a sufficient number of datasets (we will talk about how to pick the number later), we can run out analyses on each of the MI datasets, treating the dataset as if it was complete (horizontal lines and third column). After running the model on the m datasets, we can pool the results to get one single estimate with its associated variance (last column).

This method is obviously much better than the first two methods because it allows us to not throw away data, as well as to quantify our uncertainty about imputing the missing values. The only real drawback of multiple imputation is that we still don't have true data, but we can be confident enough in our estimations to compensate for that. The only better option would be to not have any missing data.

The use of multiple imputation has been steadily increasing over the past 30 years,



Figure 1.1 : Visualization of MI data

In the original data, missingness is displayed by ?'s and the imputed data is shown in the multiply imputed data as #'s. We then regress age on weight, get the results from the individual datasets, and then pool them together.

and it is now the standard for missing data. Stef van Buren, an influential author in multiple imputation did a study of academic papers, and concluded that the number of publications using or mentioning multiple imputation is growing at an exponential rate since about 1990 [1]. Thus, using multiple imputation will be advised because of its popularity and strength.

1.3 Survival

Survival analysis is a huge field, and there have been many textbooks written about it. I only plan to introduce the topics that are relevant to my case study. For a much more detailed account of survival analysis, please see [3].

Survival analysis on the whole can generally be described as the analysis of time

to event data, often in the presence of censoring or truncation (when we don't have complete information about the time of event). There are many techniques used in this field, but the main tools that we will be using are Kaplan-Meier estimates, log rank tests, and Cox regression.

Before we go on, it should be noted that often in the literature and software (and in this paper) we see terms like “death/failure” and “survivors”. This is due to survival analysis being heavily influenced and intertwined with medical studies. A more general term for these would be “event” and “those who have not had an event yet”. These terms are used because they are clear and concise, although it might not accurately describe the event at hand. For example, if we were tracking the time until a child loses all of their baby teeth; the term death would obviously not portray the event of interest, but may be used in the context to denote losing all of the teeth.

The Kaplan-Meier (KM) estimator is a nonparametric estimate of the true survival function (the probability that you survive after time t , $S(t) = P(T > t) = \int_t^\infty f(u)du$, where $f(u)$ is the unknown probability density function). It is defined as

$$\hat{S}(t) = \prod_{t_i < t} \frac{n_i - d_i}{n_i}$$

Where n_i is the risk set, defined as the number of people who have not had the event or been censored right before time t_i , and d_i is the number of deaths or events that you observe at time t_i [4]. The Kaplan-Meier estimator is very commonly used as a measure to see how different treatments affect the survival of the population in question, and is helpful in seeing at what time points survival changes the most (i.e. early or late).

The log rank test is a popular nonparametric test that researchers often use to see if two or more survival curves come from the same distribution [5]. This is a useful tool to have, because visualizing curves alone does not give us this information. We

could have two curves that look radically different due to sampling error, yet still come from the same distribution. Knowing if the survival curves come from the same or different distribution is useful because it allows us to make statements like “drug A is associated with longer survival time than drug B”.

The general log rank test is defined as:

$$\frac{\sum_{j=1}^J w_j(O_{1j} - E_{1j})}{\sqrt{\sum_{j=1}^J w_j^2 V_j}} \sim N(0, 1)$$

Where w_j is the weight of each individual (must be ≥ 0 , we will set all to be 1), and $N_j = N_{1j} + N_{2j}$ is the number of subjects in the risk set at time j , composed from the sum of the number of deaths at time j in each group, $O_j = O_{1j} + O_{2j}$ is the observed number of deaths at time j , composed of the sum of deaths from either group at time j , which leads to the desired quantities $E_{1j} = \frac{O_j N_{1j}}{N_j}$, and $V_j = \frac{O_j(N_{1j}/N_j)(1-N_{1j}/N_j)(N_j O_j)}{N_j - 1}$

Since we set all of the weights to be 1, this test, as it is, places equal weight to all of the deaths we observe. We could change these weights though to give more emphasis to certain death times. This is useful for example if we have a drug that takes a long time to start working. We wouldn’t care about early deaths, only about later times when we are comparing the survival. Putting more weight on the later deaths would help to answer this question better. It can be proven that the log rank test is equivalent to the score test on a Cox model (which will be discussed next) fit the same data with no ties [3].

Proportional hazards regression, often called Cox regression or Cox model is a modelling tool that allows us to analyze the hazard ratio of a covariate, assuming that each covariate acts to multiply the hazard ratio.

The hazard function is a survival tool that tells us the rate of events at time t ,

conditional on survivorship until time t . Mathematically, it is given by:

$$\lambda(t) = \lim_{\Delta t \rightarrow 0+} \frac{P[t \leq T < t + \Delta t | t \leq T]}{\Delta t}$$

. Cox regression is a maximum (partial) likelihood method estimator, given by:

$$h(t|Z) = h_0(t) \exp\left(\sum_{k=1}^p \beta_k Z_k\right)$$

. where $h_0(t)$ is what's known as the baseline hazard, and can be any positive function, and often times a parametric model like the Weibull is chosen. Note how it only depends on time and not any covariates. Z is a vector of observed covariates, and does not depend on time. The β s are found by maximizing the partial likelihood function

$$L(\beta) = \prod_{i=1}^D \frac{\exp(\sum_{k=1}^p \beta_k Z_{(i)k})}{\sum_{j \in R(t_i)} \exp(\sum_{k=1}^p \beta_k Z_{jk})}$$

Where $Z_{(i)k}$ is subject i 's k th covariate, $R(t_j)$ is the risk set (set of those who have not died yet at the time just prior to t_j), D is the number of distinct death times and p is the total number of covariates in the model. The betas are maximized by the Newton-Raphson method [6].

Our inference of interest is the hazard ratio, given by $\frac{h(t|Z)}{h(t|Z^*)} = \exp(\sum_{k=1}^p \beta_k (Z_k - Z_k^*))$ Where Z^* is another set of covariates. The relative risk (or hazard ratio) describes how the hazard changes between individuals with different covariates. Often times, the interest lies in what happens when all covariates are held constant, and the covariate of interest is increased one unit. This ratio will be a constant, and should not vary over time; hence the name proportional hazards. This is so because the ratio does not depend on the baseline hazard (which cancels out when taking the ratio). Using Cox regression, statements such as "Increasing the drug by one *mg* will decrease the rate of death (compared to non-users) by 30%". Cox modelling is one of the most used models in survival and medical literature.

1.4 Causal Analysis

Although we can analyze any observational data using survival analysis, unless a randomized controlled trial is conducted, we cannot make any claims about causality. In order to prove causality, we need experimental data in a randomized and controlled setting, not observational data. In an ideal world we would like to be able to do research and say that A causes B, rather than “our study says that A is associated to B”. However, the only way to get this interpretation is if we conduct a randomized controlled trial.

Randomized controlled trial (RCT) is a term that is often thrown around, but I want to be precise with its definition. An RCT is a study design that randomly assigns participants into an experimental group or a control group. As the study is conducted, the only expected difference between the control and experimental groups in an RCT is the outcome variable being studied [7]. In the simplest example, RCT is an experiment where subjects (with no knowledge of the experiment) are randomly assigned to either the treatment or the control. Thus, the only difference between the subjects should be the fact that they have or have not received the drug. This is in stark contrast to a retrospective study of observational data, where historic data of people who chose what group/ treatment they wanted to be in are studied. When making judgment on a retrospective study, we cannot be sure if the differences between the groups are due to their treatment choice, or some other factor. RCT’s are the gold standard for experiments, and should be used if possible. But often times monetary, ethical, and other factors prevent us from doing so. In this case, the best data we may be able to get is retrospective study.

However, we can frame our problem in a framework known as the Rubin Causal model, which helps get causal understanding from non-experimental settings [8]. Ru-

bins causal model is built upon the idea of a counterfactual, also known as a potential outcome. Put simply, the counterfactual is the result that we would have observed had the subject been in the other group. For example, if we were testing a weight loss drug versus a diet in to see which lead to more weight loss, if subject 1 took the drug, his counterfactual would be the result we would have observed if he had dieted. In an ideal world, we would observe both potential outcomes (i.e. how the subject would respond to the treatment and to the control, denoted $Y_i(0), Y_i(1)$ for subject i). This is obviously not possible, since we can only observe one outcome. This issue is what is known as the fundamental problem of causal inference. If we are able to get the counterfactual, we could compute the treatment effect of the treatment for each individual. However, this is not of much interest to us. Rather, we are interested in the treatment effect on the population. Two common measures of the causal effect in the population are the average treatment effect (ATE), defined as how the treatment effect changes when the population moves between treatment groups, and the average effect on the treated (ATT), which is the treatment effect of one group moving to another treatment.

The goal of randomization in RCTs is to make the groups be as similar as possible at baseline. However, in an observational study, the groups may be very different. Some baseline factor might influence how somebody picked their treatment. In the weight loss pill example, healthier people may choose the diet over the pill, whereas more women might be inclined to take the pill, so the participants in the two groups will not be similar to start with. We should try to make them more similar (i.e. balance) if we wish to emulate an RCT.

There are many ways to implement balancing in Rubin’s causal model, but the most popular is known as *propensity score analysis*. The propensity score is the

probability that the subject received the treatment given the subjects covariates. It is computed using the patient’s baseline (pretreatment) information [9]. We assume that some of the covariates play a role in deciding how the patient chooses the group, so controlling for this makes all of the patients seem similar at baseline. Propensity scores lead to group balancing, that is, if propensity scores are controlled, then our groups will have the same distribution at the baseline (i.e. propensity scores remove the confounding between pretreatment characteristics and treatment). And thus, we can treat the data like it was an RCT. The most popular propensity score methods are propensity score matching (where we match those who picked the treatment to those who did not based on propensity score similarity) and propensity score weighting (where each individual’s contribution to the average treatment effect is dependent on the inverse of their propensity score). Propensity score matching has fallen out of favor recently because there will be some data thrown away, and the balancing that takes place might not be that accurate [10]. However, propensity score weighting is still a popular method.

Getting the propensity score was historically done by logistic regression, although recently newer machine learning methods have been employed. The propensity score for the i^{th} individual is given by:

$$\hat{e}_i(X) = p(T_i = 1|X = x)$$

where T_i is treatment (1 means the subject got treatment), and x_i are their covariates. There has been a lot of debate as to which covariates to include in the propensity score; either all variables, or only relevant variables. I don’t aim to settle this debate in this paper.

Propensity scores use is justified by the propensity score theorem, which states

that if we assume conditional independence of the treatment given covariates on the outcomes, then we can also assume conditional independence of the treatment given the propensity score on the outcomes. Symbolically

$$(Y(0), Y(1)) \perp T | X \implies (Y(0), Y(1)) \perp T | \hat{e}(X) =$$

where the Y 's denote the potential outcomes. If this is the case, then the potential outcomes are independent of the treatment given the covariates. We need this to hold, because it allows us to break the connection between the covariates and the treatment choice [11]. This is also known as strong ignorability or no unmeasured confounders [12]. Once the propensity score is computed, if every individual in the study has the chance to get the treatment (i.e. $0 < \hat{e}_i(X) < 1 \forall i$), then we are able to get an unbiased estimate of the true treatment effect [13].

Now we have the probability or propensity of a subject being assigned to a specific treatment given their covariates. Its usefulness is immediately seen in the matching case. Without propensity scores, in order to find a comparison control match (i.e. an estimate for the counterfactual) for a 24 year old brown eyed, male, white graduate student (5 things to match on), we would have to find someone similar in the all of those covariates, however, with propensity scores, we would only need to find a match in the control group who had a similar propensity score (a scalar).

This paper is interested in weighting, specifically, inverse probability of treatment weight (IPTW). With IPTW, the sample is reweighted so that at baseline, the groups appear similar. These weights are given by

$$w_i = \frac{T_i}{\hat{e}_i(X)} + \frac{1 - T_i}{1 - \hat{e}_i(X)}$$

where T is the treatment and X is the covariate. This might be unstable as propensity scores approach 0 or 1, so alternate methods such as stabilized weights by Cole and

Herman or trimmed weights have been presented that reduce this issue [14]. Much more about IPTW will be discussed in the methods section.

Chapter 2

Methods

I want the framework and method used to be easy to use and understand, so that it can be discussed among clinicians and other people who don't have a statistics or mathematics background. On the same token, I want the methods and theory to be sound from a statistical point of view. There are many different theories and implementations to choose from for the three topics covered in this thesis. I aim to pick the ones that optimize ease of understanding and power of results, with the motivating example being cancer survival data. Throughout this section, decisions must be made as to what methods and analyses to use. Whenever a decision is made, I explain why it was chosen, and alternative methods that could also be used. It is my hope that I will provide enough clarity and detail so that the interested reader can intelligently apply these methods to their own data, even if the choice of methods is different than this thesis.

2.1 Multiple Imputation

It should be clear that multiple imputation is the preferred method to deal with missing data, so our first decision comes as to what paradigm to impute under. It should be noted that as long as valid imputations are produced, the choice of method to generate the imputations do not matter. However, since the base of our analysis starts with imputation, we need to make sure that we pick a good method. Everything

that follows in the analysis is dependent on our imputed data, so it is necessarily the case that poor imputations will lead to poor results be it bias, high variability, or loss in statistical power.

2.1.1 Selecting the MI scheme

There are two main divisions in modern multiple imputation: joint modelling and full conditional specification. Both have their own flaws and advantages. I will describe both, and then explain why full conditional specification is better suited for cancer research.

Before we get in to the imputation models, we need to have a firm understanding of missing data concepts. They take up quite a bit of space to explain, but they are fundamental concepts. I suggest that everyone reads appendix A.1 (even if you are familiar with MI), so that the concepts and symbols that will be used in this paper are understood.

In joint modelling (JM), we assume that the missing data mechanism is ignorable and that the data can be described by a multivariate distribution specified by the user on the rows (missing data pattern) of the data. Then, we run a sampler that draws imputations from the specified model, and updates model parameters. Since the true model parameters are unknown, they need to be estimated. This is often done by a data augmentation algorithm [1]. A pseudocode example will help better clarify the steps, as can be seen in figure 2.1, where the assumed model is a multivariate normal.

There has been extensive programming and research on using the normal model for this, and research shows that it even performs well under situations where the data has strong non-normality [15]. Some research has been done for other types of models,

1. Sort the rows of Y into S missing data patterns $Y_{[s]}, s = 1, \dots, S$.
2. Initialize $\theta^0 = (\mu^0, \Sigma^0)$ by a reasonable starting value.
3. Repeat for $t = 1, \dots, T$:
4. Repeat for $s = 1, \dots, S$:
5. Calculate parameters $\dot{\phi}_s = \text{SWP}(\dot{\theta}^{t-1}, s)$ by sweeping the predictors of pattern s out of $\dot{\theta}^{t-1}$.
6. Calculate p_s as the number missing data in pattern s . Calculate $o_s = p - p_s$.
7. Calculate the Choleski decomposition C_s of the $p_s \times p_s$ submatrix of $\dot{\phi}_s$ corresponding to the missing data in pattern s .
8. Draw a random vector $z \sim N(0, 1)$ of length p_s .
9. Take $\dot{\beta}_s$ as the $o_s \times p_s$ submatrix of $\dot{\phi}_s$ of regression weights.
10. Calculate imputations $\dot{Y}_{[s]}^t = Y_{[s]}^{\text{obs}} \dot{\beta}_s + C_s' z$, where $Y_{[s]}^{\text{obs}}$ is the observed data in pattern s .
11. End repeat s .
12. Draw $\dot{\theta}^t = (\dot{\mu}, \dot{\Sigma})$ from the normal inverted-Wishart distribution according to Schafer (1997, p. 184).
13. End repeat t .

Figure 2.1 : Normal JM imputation pseudocode

Taken from van Buuren's book Flexible imputation of missing data [1]

but by and large the normal is the most popular. This is just one implementation of a JM approach. Another, like that used in the Amelia package, uses an EM algorithm with user specified priors to make draws. Other distributions can be used, but the user will have to specify it, derive any relevant distributions, program it, and research the optimality properties.

An obvious issue arises when the data is categorical (either alone or mixed in with continuous). There has been much debate in the literature about how to handle

this situation. Some authors argue that you should just impute under a continuous distribution and round imputations to the nearest class number, and others suggest using distributions that are more suited for categorical data [1]. However, it has been shown that FCS methods are superior to JM methods for mixed categorical data [16]. A few of the most used R packages for joint modelling imputation include Amelia [17], norm [18] and cat [19].

It is my opinion that unless the user is very confident in the multivariate joint distribution, that JM should not be used. In the cancer example, there are many categorical variables and strictly positive variables to impute, so JM seems inappropriate.

On the other hand, there is fully conditional specification (FCS). In this paradigm, missing data is imputed on a variable by variable case on the columns/covariates based off of the specification of the imputation model for each covariate, given by the user. Whereas JM imputes on the rows, FCS imputes on the columns. This theory goes by many names, including partially compatible MCMC, iterated univariate imputation, and chained equations [1]. These full conditionals should factor to specify the joint distribution. In the JM setting, the user must give a k dimensional model, however in the FCS setting, the user must give k one dimensional models. The goal is to sample from

$$P(Y, R|\theta)$$

By sampling from the full conditionals

$$P(Y_j|Y_{-j}, R, \phi_j)$$

In this notation, Y_{-j} means all of the columns with missing data except for j , and Y is the fully observed columns (which could possibly be empty). A pseudocode example

can be seen in figure 2.2. Note that the previous imputations enter the current imputation only through the relation with the other variables, and not directly. Because of this, convergence is often seen within 20 iterations [20]

1. Specify an imputation model $P(Y_j^{\text{mis}}|Y_j^{\text{obs}}, Y_{-j}, R)$ for variable Y_j with $j = 1, \dots, p$.
2. For each j , fill in starting imputations \dot{Y}_j^0 by random draws from Y_j^{obs} .
3. Repeat for $t = 1, \dots, T$:
4. Repeat for $j = 1, \dots, p$:
5. Define $\dot{Y}_{-j}^t = (\dot{Y}_1^t, \dots, \dot{Y}_{j-1}^t, \dot{Y}_{j+1}^{t-1}, \dots, \dot{Y}_p^{t-1})$ as the currently complete data except Y_j .
6. Draw $\dot{\phi}_j^t \sim P(\phi_j^t|Y_j^{\text{obs}}, \dot{Y}_{-j}^t, R)$.
7. Draw imputations $\dot{Y}_j^t \sim P(Y_j^{\text{mis}}|Y_j^{\text{obs}}, \dot{Y}_{-j}^t, R, \dot{\phi}_j^t)$.
8. End repeat j .
9. End repeat t .

Figure 2.2 : MICE FCS imputation pseudocode

Taken from van Buuren's book Flexible imputation of missing data [1]

One of the major criticisms of this method is that in order for there to be a guarantee that we are sampling from the correct distribution, we need to ensure that our full conditionals are compatible, i.e. that they factor into the proper joint. This is very hard to check in practice, but multiple studies have shown that even when the models are highly incompatible, FCS methods are very robust and produce proper imputations [21]. FCS allows us much more flexibility than JM does, and it handles discrete and categorical data much better than JM does [16]. Some popular R implementations of FCS include MICE [20], mi [22], and BaBooN [23]. I will be

using MICE in the applied section of this paper, and from now on, MICE and FCS will be used interchangeably.

The user is going to have to specify something, there is no escaping that, but it is easier for the average person to be able to define a single distribution and model rather than to guess at a multivariate distribution, particularly if it is high dimensional. In addition, in the survival analysis setting, there will naturally be strictly positive and categorical variables. Trying to fit a parametric distribution with these stipulations will be very hard if not impossible, so we will be relegated to using a general distribution (like the normal), which will certainly elicit a poor fit. So, the full conditional specification certainly seems like the more appealing option. In an ideal world, we would have complete data, and would not need to resort to imputation. But since we don't have complete data, we must choose one method and accept its strengths and weaknesses.

In order to use FCS methods, the missingness in our data to be MCAR or MAR. It can work with MNAR data, but it requires some extra modelling assumptions. This is a seldom observed case in practice, so the interested reader may check [20] section 6.2 for a detailed look at this. T tests have been proposed to test if the data is MAR or MCAR, but this is of little use for us, because we only want to know if the data is MNAR, which is impossible to test since testing for MNAR would entail us using information that is impossible to get [24]. Luckily, we can safely assume MAR if there is reason to believe that some of the covariates collected account for the missingness [1].

It should be noted that in the real data we will use, the response variable is fully observed, but the covariates have a lot of missingness. If it were the case that we had missingness in the survival time, then the methods described above might not work.

They might fail because the unobserved times may follow a different distribution than the observed times. This is cleared up by Zhao et. al in 2014 through Kaplan-Meier MI [25]. This is beyond the scope of this report though so I omit its details.

2.1.2 Setting and checking the model

Once we have the correct assumptions, we need to set up our full conditionals imputation models. This may take a while for large datasets, but the extra time spent will ensure a better model. We choose what predictors will go into imputation, and what method to use (regression, predictive mean matching, logistic regression, trees, etc.). We should choose predictor variables that help explain missingness, as well as those we are doing inference on, as to avoid bias [1]. For variables that are derived from others, we impute the others and then compute that variable, in a process known as passive imputation. Since our data is of manageable size, I include any reasonable predictor that doesn't induce collinearity for predictors in the imputation models. With large datasets, we may need to perform variable selection before specifying the models, so that it doesn't become unmanageable.

Since FCS is an iterative process, we must choose how many iterations to do until convergence. The older literature suggests 5 iterations are enough, but with modern computation, we can easily exceed this, even with large data [1]. A good way to assess how many iterations to run is to look at the diagnostic plots (which will be talked about later), then add 5 iterations to the number at which we assume convergence is achieved. Due to the nature of FCS, convergence is often very quick, often as soon as 5 iterations. As well, we need to decide how many datasets to impute. The early literature argued that 5 would suffice, but modern literature argues for more, since it will cut down on simulation error. Many different authors have different criteria's, but

a popular criterion is to impute as many datasets as the 100 times the percentage of cases in the analysis with missingness. With the speed of computers and availability of storage, many authors now suggest using more imputations [1].

Once we have determined how many iterations and imputations to run, MICE is ran. Depending on the model specifications, it should not take too long for small datasets (seconds or minutes), but may take hours for larger ones. FCS models often converge quickly, so after convergence, we are just taking draws from the missing covariates posterior. The first few iterations may be considered as burn in, and the rest as samples. The value at the last iteration of each chain as the sample from the posterior.

We need to verify that our imputations are valid once we complete them. First, we need to see if our chains have converged. Since MICE is an MCMC method, we should check the chain for irreducibility, aperiodicity, and recurrence. To determine when the chain has converged, van Buuren suggests that “Convergence is diagnosed when the variance between different sequences is no larger than the variance within each individual sequence” [1]. There is some research (but not from the MI perspective) about tests to check for convergence, and a popular test is Gelman and Rubin’s \hat{R} scale reduction factor test [26]. This test is often used in conjunction with visual tests. Assessing convergence by looking at all of the values over m imputations and k iterations would be very hard to visualize because there would be so many chains, so often times, we will choose to observe a statistic (like the mean) of the chain and assess on that.

Once convergence is assessed, we need to check that the values imputed are valid and come from the correct posterior. This will serve as our model checking and validation. The overarching idea that we need to pay attention to is does the data

look like it could have been real data. We can assess this in many ways, including density plots, box and whisker plots, etc. This is a visual task, and there is no statistical method to validate this.

This whole process can be very time consuming, because every time we want to make a change in the methods used, we have to rerun the algorithm and reassess our results. But once we find the setup that works for us, we don't need to repeat it again. So, while it may take a lot of time now, setting up a proper model will save us even more time in the future.

2.1.3 Combining the MI estimates

Once the m datasets are imputed, we may run any valid analysis on each imputed dataset *individually*, treating each of the m datasets as if it was complete. I am a strong advocate of running the model with the available cases if possible before running it on the MI data, so that we can assess the appropriateness of the model. As well, running the model with the available cases will give us a clue as to what to expect from the MI analyses (such as sign of the coefficients or level of significance).

On the m imputed data sets, we may then apply Rubin's rules [2] to pool our estimates. Rubin's rules are essential for using multiply imputed datasets, so we need to investigate them thoroughly.

Rubin's rules are a set of rules that guide us in making inference from multiply imputed data. They will give us a single point estimate, as well as the proper variance for the quantity we have in mind from the m imputed datasets.

Rubin's rules involve three parts. The first is getting an estimate of the population estimand Q . To get this, define \hat{Q}_i as the estimand evaluated from the data in the i^{th}

dataset. Then, take the average over all m datasets to get a single estimate \bar{Q} .

$$\bar{Q} = \frac{1}{m} \sum_{i=1}^m \hat{Q}_i$$

The estimates are not set, and there is variance associated with them. The first form of variance is the “within ” variance, or the variance of each estimate \hat{Q}_i . Define the variance of the i^{th} imputed dataset as \bar{U}_i , then the overall within variance is computed as

$$\bar{U} = \frac{1}{m} \sum_{i=1}^m \bar{U}_i$$

The last form of the variance is the “between datasets” variance. This is the variance associated with the fact that we have missing data. It is given by

$$B = \frac{1}{m-1} \sum_{i=1}^m (\hat{Q}_i - \bar{Q})(\hat{Q}_i - \bar{Q})'$$

The total variance for our estimand is given by

$$T = \bar{U} + B + \frac{B}{m}$$

The last term is our simulation variance, and its existence is proven by Rubin in [2].

The theory of inference with Rubin’s rules is rooted in the assumption that under repeated sampling, the complete data quantity of interest is asymptotically normally distributed with mean Q and variance U , where U is the variance of $(Q - \hat{Q})$ [1]. We don’t have the true population variance, so we must use what we have from the sample, namely T , the MI total variance. With this assumption, we know that

$$\frac{Q - \bar{Q}}{\sqrt{T}} \sim t_\nu$$

And the degrees of freedom is proven to be

$$\nu = \frac{\nu_{old}\nu_{obs}}{\nu_{old} + \nu_{obs}}$$

Where $\nu_{obs} = \frac{\nu_{com}+1}{\nu_{com}+3}\nu_{com}(1 - \frac{B+B/m}{T})$, ν_{com} is the hypothetical complete sample degrees of freedom, and $\nu_{old} = \frac{m-1}{(\frac{B+B/m}{T})^2}$ [27].

Rubin's rules assume normality, so if our statistic in mind is not asymptotically normal, we need to transform it towards normality before pooling. There have been some research about how to pool non normal quantities, but current research shows poor results and power when doing so [28]. It should also be noted that we have discussed the univariate case, but this easily extends the case with multivariate estimands. If we have multivariate estimands, we can still use Rubin's rules, but will need to replace the notation above with vectors for \hat{Q}_i and variance-covariance matrices wherever we have variance. We now have a powerful framework to get valid inference from data with missingness via multiple imputation multiply imputed data, so let's now see how to fit in other types of analyses in the MI paradigm.

It should be noted that there is another way to work with the multiply imputed data. This method is colloquially called the stack method. For the stack method, we take all of our imputed data and stack them one on top of each other to get one huge dataset of size $(m * i)$ rows and j columns. Under the stacked method, unbiased estimates of quantities of interest can be produced, but the estimates of variance will be too small (since we are artificially increasing the sample size) [1]. Thus, the stacked method is a poor choice for running any hypothesis tests or quantifying uncertainty. It is not useless though. The stacked method is useful when we want to analyze just one plot instead of m for model checking. As well, the stacked method may be useful in situations where we partition categorical data on an imputed variable and then look at the percentage in each category. Under the averaging portion of Rubin's rules, we are not guaranteed that the percentages will sum to unity, but under the stacked method we are.

2.2 Survival analysis

Now that we have the multiple imputation datasets created, we may run our analysis on each of them. As a general rule of thumb, we should run our desired analyses on the original data to get the available case estimates, to get an idea of what to expect and to check if the model assumptions are met. Because we are working with cancer data, we are interested in some basic survival quantities, such as Kaplan-Meier survival estimates, log rank test to test for similarity of curves, and Cox regression. Following Rubin's rules, we run the individual analyses on each of the m datasets, and then pool our results. In this section we will discuss each type of survival analysis in the MI setting and the issues associated with it.

2.2.1 Kaplan-Meier Survival Curve

Analysis for the Kaplan-Meier estimate is quite simple in the non MI setting, but special care should be taken in the MI setting. First, we need to clearly define what the groups and population are, and what constitutes an event of interest. A very common mistake that researchers make is to try to frame a competing risks problem as a Kaplan-Meier problem. We also need to be sure that we have noninformative censoring, that is, knowing that the individual is censored tells us nothing about their survival probability. Once we have checked all of these, we can compute the Kaplan-Meier curve on each of the m datasets. For simplicity, in this section we assume that the Kaplan-Meier curves are run on a dataset with only subjects who take a treatment or a control. Now, we could pool these estimates, but that would be ill advised, because the Kaplan-Meier curve is not normally distributed. To get around this, it has been proposed by Marshall et. al to take the complimentary log log transformation of the survival estimates before pooling [28]. We can make this

transformation, pool our results, and then back transform to get the pooled KM estimate.

In the MI setting, an interesting situation may arise when the last event (and thus the range of survival time) differs between the imputed datasets. This is the result of a person with a long survival time being put in different groups via imputation. We can deal with this by either extending the last observed Kaplan-Meier estimate out until the last event time, or truncating all of the imputed curves at the minimum time of last event. Alternatively, we could use the stack method instead. In traditional analysis, we would not extend out the Kaplan-Meier curve out past the last event, but if we have wildly varying imputations, this might be a good option, so that we can make inference between curves and are not hampered by one poor imputed dataset. The decision of what to do is up to the researcher and depends on the nature of the problem.

2.2.2 Median Survival Time

One of the main tasks that clinicians are interested in is the median survival time of each group, which is the smallest time that the survival probability function for the group is less than 0.5. The median is the preferred method of central tendency in survival analysis because often times the survival times are right skewed, making the mean a poor estimator of the truth. Finding the median in the MI case is quite simple, as it is the first time that the averaged Kaplan-Meier curve crosses below 0.5. We would also like to have the variance at the median. The first way to obtain it is to pool the Greenwood variance associated with each time point and then take the average as the variance at that time point. But the Greenwood estimator tends to underestimate the true variance [3], and taking the mean and variance of the variance

doesn't make much sense. A better solution for this issue is to derive the variance of the median by the "reflection method". In this method, we first fit the MI Kaplan Meier curve, and then construct a 95% confidence interval for all time points using the total variance obtained from Rubin's rules pooling. The median is defined as the first time when the pooled MI curve crosses 0.5 survival line, and the lower and upper bounds are the medians of the upper and lower confidence bands. This method is preferred because it uses the variance we actually have, and is much more robust to poor imputations.

2.2.3 Log Rank Test

Now, we will have a pooled estimate of the true survival curve for each group. In the typical setting, we might want to look to see if these curves are similar to each other, so we can determine if the treatment really prolongs survival time. We would do this with a log rank test under the regular setting. However, we should not be deceived. We have an averaged survival curve, they are not constructed in the same way that a regular Kaplan-Meier curve is, so we cannot get the quantities that we would need to compute the log rank test. However, we can still get the pooled log rank test. To do so, we can do one of two things. The first is to run the log rank test on each of the datasets and then pool the results via Rubin's rules. This is the logical way to do it, but under this scheme we will run into a multiple comparison problem. In addition, many statistical packages only report the chi square version of the statistic, meaning we would have to reprogram it in order to use Rubin's rules for pooling. Another option is to run a Cox regression on just the group in question, since this is equivalent to the log rank test under no tied times [3]. From the Cox regression, we can obtain the score test. However, in order to do this, we need to know who is in the risk set.

But the concept of a risk set doesn't exist in the MI setting. Luckily, the Wald test is asymptotically equivalent to the score test, and the Wald test is very easy to obtain. So we can use the Wald test of the coefficient from the Cox model as a proxy for the log rank test. In this way, we get a statistic that calculates what we want, while still making sense in the MI context.

2.2.4 Cox Proportional Hazards Model

We would now like to investigate the hazard ratio of different baseline covariates and treatments via the Cox proportional hazards model. The overall goal will be to fit a Cox model with baseline covariates, check to see if it passes the proportional hazards assumption, and then add in the treatment variables to see how they affect the hazard. It is known that the Cox regression coefficients are normally distributed, so there is no issue in pooling, but we do need to be careful about checking the proportional hazards assumption. The very first thing that we need to do is check to check the available case model to assess if we have proportional hazards. If one of the covariates truly is dependent on time, adding imputed data isn't going to change that, so checking the available case analysis is a good sanity check. The way we go about checking to make sure that we have proportional hazards is checking to see if the Schoenfeld residuals are uncorrelated with time for each covariate in the Cox model. The Schoenfeld residuals are tedious to explain and derive, and add no value to this thesis. But knowing that they are partial residuals that that are formulated to be independent of time should suffice to understand this paper [3]. We can check a test for correlation or observe a spline fit to the residuals to determine how uncorrelated they are, but the latter is usually preferred in practice. In cancer research, the most common test to look for proportional hazards is to plot the spline fit (often cubic)

to the residuals along with the 95% confidence intervals, and see if any straight line could pass through the bounds. Because the residuals are independent of time, a straight line over time signifies that the hazards are proportional [29]. There isn't an official name for this method, but the straight edge method seems to be a fitting name since you can check it by placing a straight edge between the confidence bands. If this is the case, then we say that the covariate in question follows the proportional hazards assumption.

We have discussed how to check the proportional hazards assumption in the available case scheme, but how can we do this in the MI setting? We can take our imputed data and fit a Cox model on each of the m datasets, and pool them easily. But how is the best way to check the proportional hazards assumption. We can go about this in a few different ways. The first is to check the assumptions on each individual model fit to each dataset. This may prove to be an arduous task (especially with large m , but with graphical tools such as shiny, this isn't too bad). We could also superimpose all of the spline fits on one plot, and see how the shape and general trend compare to the available case analysis. We can also use the stack data to get just one set of plots, but the straight edge method will not work here since the errors are too low. Rather, we would just need to assess the shape of the spline fit in comparison to the available case method.

Once we have verified that the model follows the proportional hazard assumption, we may trust its results. We can now add in our treatment covariates, and analyze to see how they affect the hazards. An interesting thing to look at will be how the hazards change from the baseline once we factor in the treatment.

2.3 Propensity Score Analysis

Now that we have laid down the theory for analyzing the survival section for clinical relevance, we can move on to the causal analysis part. While there is a lot of preparatory work that goes into the theory of it, the results that can be obtained using causal analysis framework and propensity scores is much stronger and appealing than conventional analysis. Although no statistical method will give us a causal relation, the results from causal analysis will be much more similar to the results we would have got from a RCT. Propensity score methods are an easy to understand yet powerful tool. The use of propensity scores justified in Rosenbaum and Rubin's 1983 paper [9]. Our overall goal is to estimate the average treatment effect in a setting where the initial study was not an RCT. We will use the propensity scores to balance the groups so that it seems more like an RCT.

We will need to make a few decisions along the way. Our very first decision comes when deciding how to use the propensity score. There are four main uses in the survival literature: Matching, stratification, weighting, and covariate adjustment [14]. The goal is to balance the treatment and control groups, such that the only difference between the groups is due to the treatment received, and not any underlying factor. All of these methods will help us to examine the average treatment effect, but each goes about it in a different way. Covariate adjustment and matching have fallen out of favor in the literature recently, but weighting and stratification remain very popular. We will be using weighting in our real data analysis, so the main focus will be on that, but the methods discussed will work with any propensity score method. Whatever method is chosen will need to be run on the MI datasets. The stacking method described before would obviously be inappropriate, as the sample size will be too large, and with high probability, subjects will be matched to themselves. Thus,

the analysis will not be valid

Two methods are described in Mitra and Reiter about how use propensity scores in the MI setting [30]. In both methods, the propensity scores are first computed for each MI dataset, as we would normally do in the analysis part of the MI process. However how the two methods use the propensity scores are different. In the first method, known as the within method, the propensity score method is done within each MI dataset and then pooled. For example, if we wanted to find the ATE, we would estimate the ATE in each dataset, and then pool via Rubins rules. The other method, known as the across method, takes the m estimates of each individuals propensity scores, average it so that every subject has one averaged propensity score, and then the method is run. For example, in matching, the propensity score is found and then a matched control set is created from it. Both methods have their pros and cons, and are appropriate for different scenarios. However, the treatment variable may itself have missingness, and thus needs to be imputed. In this situation averaging across datasets does not make sense (since there is no guarantee that a given subject in imputation i has the same treatment in imputation j), so we cannot determine if the subject is a case of a control, thus matching will be impossible. When this is the case, we must use the within method.

Now that we have discussed the method about how to use propensity score methods in the MI setting, lets discuss how to actually get the propensity score. From now on, propensity score weighting will be the only method discussed, because that is what will be used in the application section.

Different propensity scores will be obtained according to what pretreatment covariates we use in the propensity score model, so we need to be sure that model is fit with clinically relevant and meaningful predictors. Our overarching goal is to account

for any pretreatment covariate that confounds the selection of the treatment. There has been significant debate among statisticians about how to set up these models, by either throwing in every possible variable into it, or only include ones known to affect treatment selection. I don't plan to settle this debate, but since we are in a setting where simplicity is a goal, I plan to use only pretreatment covariates deemed to be important (through consultation with subject matter experts) to treatment selection. This is the method that Peter Austin, a well-known propensity score researcher recommends [14].

Propensity scoring using logistic regression has been historically used, but with newer machine learning methods, we are able to get better propensity score that induce more balance. In recent years, boosting has become very popular[31].

The goal of weighting is to create a pseudo-sample that is balanced, by up weighting samples that look like treatment cases, and down weighting those who do not. Two methods have been suggested to check for balance.

The first is known as standardized bias. For each pretreatment covariate we wish to balance, we see how similar the cases and controls are by observing $|\bar{X}_{k1} - \bar{X}_{k0}|/\hat{\sigma}_k$, where the barred Xs denote the weighted means of the covariate in the treatment and control groups, and the σ is the original standard deviation. Typically, standardized bias below .2 indicates good balance [31].

Another common method is the KolmogorovSmirnov test. In this nonparametric test, the empirical cumulative distribution function (ECDF) is computed for the two (weighted) groups. Then, the maximum distance between the two ECDFs is calculated. Its pvalue is found via the permutation test.

Both of these methods offer us tools to assess balance in the data when weighted by the propensity scores. We can use the tools to our advantage alongside of a boosting

algorithm to get good balance. In boosting, a simple piecewise linear function is fit to the data, and after every iteration, a new piecewise linear function is fit to the previous models residuals. We can boost our data, take the propensity score at every iteration, weight out sample, and then check the balance. The goal though is to find the weights that minimize either the standardized bias or the KS statistic.

Once we have obtained our optimal propensity scores, we weight the data by them. Then, we check to see if we have balance. The first thing to look at is the distribution of the propensity scores. We would like to see some overlap between the treatment and control propensity scores. Overlap indicates that subjects in both groups are similar to each other, and can be compared. If the propensity scores don't have any common support, then we have not properly balanced. The next thing to check is if we truly have achieved balance, and we can check these via the two tests described above. Once we have our propensity scores, we need to go about checking the treatment effect. We have no guarantee that the model we set for our propensity score is correct, so many authors advocate including troublesome variables in the analysis of the treatment effect (this is known as a doubly robust method) [12]. We will be using the within method, so for each MI dataset, we compute the treatment effect from the weighted data, and then combine the estimates via Rubin's rules.

Once an acceptable propensity score model is selected, we will need to pick what type of weighting we will do. Many exist, but the most popular are X, Y, Z . We will then run our Cox model again (as in the survival section), but we will factor in the weights. Then, the results that we receive can be viewed as if they were from a RCT. As well, we can go ahead and analyze them as such, and draw causal inference. I need a lot more work here.

Chapter 3

Application

3.1 Data Explanation

Now that the theory is in place, we can apply it to some real data. The dataset that I chose to analyze is a dataset from MD Anderson Cancer Center, with permission from Dr. Bugano, Dr. Ibrahim, Dr. Hess and [whoever else needs to be thanked]. The IRB protocol is RCR03-0931. This dataset has historical records of 1514 MD Anderson patients who have had breast cancer that has metastasized to the brain. Metastases are often shortened in speech and in paper to the word mets. The dataset consists of 111 covariates, with missingness ranging from 0 to 99%. Some predictors are metadata, and rare tests, so they will not be considered. Ignoring these, the missingness ranges from 0 to 65%. Included in these are 90 different covariates, a few different treatments, as well as survival endpoints (which are all observed). The data can be broken down into a few broad categories, as can be seen in table 3.1. There are too many covariates to completely explain here, but I've listed the ones relevant to our models in table 3.2

To get a feel for how the data is missing, in figure 3.1 we see a plot of the missingness in the data.

This data is exemplary for demonstrating thesis ideas because it is a large retrospective study (pulled from a database), survival amenable, has missingness that is a prime candidate for imputation, and has treatment variables that are not given in

Type	Example
Subject data	Age range, race, date of birth
Cancer data	TNM staging, type, receptor status
Pre brain mets data	Treatment types
Post brain mets clinical observations	Seizures, headache, nasuea
Post brain mets data	Treatment type, type of brain mets
Survival data	Survival time after brain mets, censoring indicator

Table 3.1 : Data Categories and Examples

an RCT.

Our first step is to clearly define what we would like to find. There are many interesting questions we could ask and answer from this data because of the amount of data available, but the question I will focus on here is survival after brain mets from breast cancer in two different settings. In the first, we will explore the treatment effect of Capecitabine (a chemotherapeutic agent) versus other chemotherapeutic agents versus no treatment. In the second, we will look at the effect of two HER2 directed drugs (Lapatinib versus Trastuzumab) versus no HER2 targeted drugs in a subset of the patients who are HER2+.

It isn't vital to understand the entirety of cancer and its treatments for understanding this analysis, but the interested reader may want to look at appendix A.2 for a very basic overview of breast cancer and the methods of how different drugs

Name	Percent Missing	Meaning
hrher2	5	Categorical variable: The hormonal receptor and HER2 receptor status of the subject
agebrainmet	0	Indicator: Age greater or less than 60 at time of brain mets
timedx	1	Indicator: Time (years) from breast cancer diagnosis to brain mets diagnosis greater or less than 6 years
site5	1	Indicator: First metastasis was to brain
race2	0	Categorical: White, Black, Hispanic, other
priorn	0	Indicator: Number of prior treatments in metastatic setting before brain mets
braintype	4	Categorical: Single, multiple, Leptomeningeal disease
controlled	12	Indicator: Extracranial progression of brain mets
capeothno	18	Indicator: Capecitabine, other, or no chemotherapeutic treatment. Treatment variable 1
lapatrasno	18	Indicator: Lapatinib, Trastuzumab, or no HER2 treatment. Treatment variable 2
os	0	Overall survival (months)
dead	0	Indicator: death indicator
her2	10	Indicator: HER2 receptor status

Table 3.2 : Table of important covariates to be used in the analysis

work. For a much more detailed analysis and other clinically relevant questions, see the paper by Bugano, Hess, and Berliner. This is the project that this research was



Figure 3.1 : Visualization of missingness in the cancer dataset

Along the horizontal axis is the subject, and the vertical axis is the covariates. **Green** denotes observed values whereas **red** is missing. The covariates with the highest missingness are three genetic measures, as well as some clinical assessments.

forked off of, although it will probably not be published by the time this thesis is.

3.2 Imputation

We first need to impute the missing data. This is a challenging task, because of the attention and care that needs to be given to imputing about 90 covariates with missing data. But we need these covariates to be imputed properly for many reasons, such as; they have the potential to be useful as predictors for other covariates, they might be something we are actually analyzing (now or later), we have spent the money to collect the data, and it strengthens the MAR assumption. As well, it is my opinion

(and probably a consensus among applied statisticians) that is better to have too many covariates than not enough. After all, variable selection can be performed if there are too many covariates.

Our data is quite high dimensional, and there are a many binary variables as well as a handful of strictly positive covariates, thus JM imputation seems inappropriate. Instead, FCS models seem better suited. We will be using the R package mice [20] because it is easy to use yet powerful. There are other software implementations in different languages (such as PROC MI in SAS, ICE in Stata, and package mi in R), but I found mice to be the most flexible while also being powerful and easy to use.

The first task we need to do is to assess the missing data mechanism. As we have discussed before, there is no formal statistical test to determine what the mechanism is. It is very unlikely that the data is MCAR (which we typically associate with random/accidental deletion), so it is between MAR and MNAR. We have so many different covariates, and it could reasonably be assumed that the missing data we have could be explained by the type of disease, its stage, the subject's age, their standardized assessment, and their survival time, among other things which we have collected. So it would be reasonable to assume that the missing data mechanism is MAR, and thus imputation can be confidently used.

Now that the missing data mechanism has been assessed, the imputations need to be set up. For each covariate with missingness, we need to decide the form of the imputation model that will be used for imputation, and what predictors will be used in it. Most of the covariates that needed imputation were either binary or categorical, so the most popular model chosen were logistic regression, multinomial logit regression, or predictive mean matching. The method that was most appropriate for each situation was chosen. The continuous variables were often selected via regression

or predictive mean matching. I decided to be very forgiving, and use nearly every reasonable predictor for each missing covariate. I did this to bolster the MAR claim, and avoid variable selection. Van Buuren proposes measures called influx and outflux to determine how worthy and connected each covariate will be as a predictor [1]. An ideal variable to use as a predictor would be one with an influx near zero and outflux near one. I used all predictors except those that had very poor influx and outflux. Unsurprisingly, the covariates with poor influx and outflux were those who had high missingness or poor relatedness to the rest of the data, as can be seen in table 3.3.

Once the model and predictor choices were made, the imputations were run and tuned, and checked by trial and error. This took a considerable amount of time, because after every change made, the algorithm needed to be reran and the convergence and imputations needed to be assessed. As well, changes in model specification were rarely localized to that variable, and often affected others.

It took about three weeks to set up and check the models. This was because the number of covariates was large, and checking the imputations after a change was time consuming. It would not take this long for a smaller dataset. Creating valid imputations is a skill that lies somewhere between an art and a science, so it takes the theory to know what to do, and trial and error to see if you’ve done it correctly.

For the final MI dataset, it was decided to impute $m = 50$ datasets and 40 iterations for each. Mice generally converges quickly (within 5 or 10 iterations), but by setting the number of iterations so high, it is as if we are setting a burn in period, and then taking our sample. The number of imputed datasets was selected to be 50 because in general, the number of datasets should be more than the imputations [32], and while there is no consensus about how many imputations to do, the modern research argues that the more the better. Research by White et. al says that you

	Percent Observed	influx	outflux
ki67	0.17	0.83	0.12
brca	0.05	0.95	0.04
p53	0.01	0.99	0.01
symptoms	0.59	0.37	0.35
seizures	0.58	0.38	0.34
headaches	0.58	0.38	0.34
nausea	0.58	0.38	0.34
chocking	0.58	0.38	0.34
balance	0.58	0.38	0.34
weakness	0.58	0.38	0.34
language	0.58	0.38	0.34
cognition	0.57	0.38	0.34
ECOG	0.35	0.62	0.16
gpaecog	0.35	0.62	0.16
gpasum	0.31	0.65	0.11

Table 3.3 : Percent observed and influx and outflux of the worst predictors. Ki67, brca, and p53 are cancer markers, ECOG and GPA are performance scores

should choose m to be about 100 times the percentage of incomplete cases (for the analysis at hand) [33]. The data used in our analysis has about 30% missingness, so imputing 50 datasets was the chosen number.

After the final model for each covariate with missingness has been set up, we need to run it and save the results. For 50 datasets, 40 iterations, the algorithm runs in about 4 hours, and for 50 datasets with 100 iterations, it took 11.5 hours

on a computer with 4 GB of ram and 4 cores. While this seems like a long time, this process only needs to be done once and requires no human interaction, so it can be run overnight and then never need to be touched again. The imputations were run for 100 iterations to see how the run time scaled, as well as to check how the chains behaved and to see how the analyses differed. The results between 50 and 100 iterations were very similar. As well, there is hardly any confidence to be gained going from 50 to 100, and having such large objects in memory can be harder to work with. This is why 50 MI datasets, iterated 40 times each were chosen.

We need to check our final imputations for convergence and reliability. Convergence is assessed by looking at plots of covariate mean and standard deviation by iteration. Diagnosing convergence for binary and categorical variables is a bit tricky, because the mean of a categorical variable is nonsensical, but we can get a good idea of convergence by looking at if the variance remains constant. And for binary variables, knowing how the groups are coded and looking at where the means are can give us an idea of healthy convergence. For example, if we had a variable coded as 1 for underweight and 2 for overweight, and we expected there to be much more overweight imputations than underweight, seeing a mean of 1.8 (indicating 80% were imputed as overweight) would be reasonable, but 1.2 would not. According to van Buuren “the different streams should be freely intermingled with each other, without showing any definite trends. Convergence is diagnosed when the variance between different sequences is no larger than the variance with each individual sequence” [20]. There are 80 plots to check, so I cannot show all of them in this paper, I only show some interesting ones as a select few can be seen in figure 3.2 and 3.3. Looking at these plots, convergence certainly seems to be the case. Other authors suggest using a more formal statistical tests such as \hat{R} , but since most of our interesting variables

are categorical, this does not make much sense.




Figure 3.2 : Selected plots of continuous variable imputation mean and standard deviation by iteration

Once the convergence is diagnosed, the validity of the imputations needs to be inspected. Diagnostic plots are viewed to ensure that the imputed data is similar enough to the real data. Common plots include density plots of each MI dataset compared to the complete cases, as well as bivariate scatterplots for imputed variables. A few of the plots have been replicated here!!! Still need to do this. Once again, all of the plots cannot be displayed in this paper, but some important ones are recreated. As we can see, not all of the imputed data follows the distribution of the observed data exactly, but for the majority of the plots, the data look like they could have been real data had they not been missing.

Now that the imputations are done, let's have a look at the breakdown of the data. In table 3.4 we can see how the MI data compares to the available case data, broken




Figure 3.3 : Selected plots of binarys variable imputation mean and standard deviation by iteration

down by if the subject had any systemic therapy. As noted before, this was computed via the stacked method because of the percentages.

3.3 Survival Analysis

Now that the datasets are imputed, we are ready to run our models on them. Before we begin though, we should check the models on the available cases, to make sure that the model assumptions are met, and to get an idea of how the importance of each part of the model. The available case models (Kaplan-Meier, Cox) were run and the assumptions were checked, and all of them passed. You can see the results, alongside the MI values throughout this section.

It should be noted that in all of our survival analyses, we will be doing a landmark

	Sys therapy available case	Sys therapy MI	No Sys therapy available case	No Sys therapy MI
Age (mean,sd)	51.4(10.8)	51.2(10.9)	52.7(11.9)	52.9(11.4)
Breast Cancer subtype				
HR+/HER2-	27%	31%	28%	33%
HR+/HER2+	19%	18%	12%	13%
HR-/HER2+	22%	20%	15%	12%
Triple negative	32%	32%	45%	42%
Prior therapies for stage 4	1(0-3)	2(0-4)	2(0-4)	2(0-4)
Single brain lesion	25%	23%	23%	20%
Controlled extra-cranial	40%	40%	35%	36%
ECOG 0-1	84%	70%	53%	40%
Local Therapy				
Resection Alone	5%	5%	9%	7%
SBRT alone	13%	12%	9%	8%
WBRT	60%	59%	52%	53%
Resection/SBRT+WBRT	12%	14%	10%	8%
no local therapy	10%	10%	20%	23%

Table 3.4 : Characteristics of available case data versus MI data

analysis. Landmark analysis means that we don't start the analysis at time 0, rather, we start it at a different time later than 0. In Dr. Hess's words, "Since the brain mets treatment data was necessarily determined after the diagnosis of the brain met, it is not appropriate to use this data as baseline covariates in the analyses. Only

covariates known at the time of diagnosis can be used in this fashion. We can do a landmark analysis by estimating when the vast majority of patients would have had their brain met treatment choices started and starting our analyses at this point ". After speaking with cancer experts (Dr. Bugano and Dr. Ibrahim), this landmark time was determined to be 2 months.

The first result that we will check is the Kaplan-Meier curves for the imputed data. Noninformative censoring seems to be a valid assumption. The pooled KM estimate was found using Rubin's rules, but under a complimentary log-log transform as suggested by [28] to get the survival curves towards normality. The median and confidence interval about it was computed as the median of the upper and lower confidence bands.

The first question we would like to look at is the survival curves for chemotherapeutic drugs. This can be seen in 3.4. The available case and MI analyses look similar, but the MI data seems to give a lower median survival time for the chemotherapeutic drugs. For not taking any chemotherapeutic drugs though, the median increased.

For the HER2 targeted drugs the available case analysis shows that Lapatinib and Trastuzumab are quite close to each other, while having no HER2 directed treatment being much lower. The MI analysis says about the same, but once again gives lower values for the median survival time, as can be seen in figure 3.5.

Now that we have a visual of the curves, we would like to see if there is actually a difference between them. To do so, the log rank test needs to be run on them. We can also get an approximation for the log rank test on the MI data via the Wald test on the pooled Cox model fit only on the treatment. Recall that we are not able to get the exact log rank test because in doing so, we would need to compute either the likelihood ratio test or score test, both of which would include calculating the risk




Figure 3.4 : Landmarked Kaplan-Meier curves for chemotherapeutic drugs, AC and MI data

set, which is not possible in the MI setting. It has been suggested to pool the chi square statistics via methods presented in Marshall et al 2009, but even they say that this method is poor [28]. So, our only real option is to use the Wald test (which is very easy to compute), and use that value as a proxy for the log rank test (they are asymptotically equivalent). The results for the overall test and for each comparison can be seen in table 3.5 and 3.6. The AC and MI results are quite similar. However, for Capecitabine vs other chemo drugs, we see a relatively high p value. Depending




Figure 3.5 : Landmarked Kaplan-Meier curves for HER2 drugs, AC and MI data

on the acceptable rate of significance, different conclusions might be drawn between the two analyses. In this study, the level is $\alpha = .05$, so changing conclusions is not an issue.

Now that we have estimate of the survival curve, we may set up a model to observe how changes in some baseline covariates change the hazard. We will do this with the Cox Proportional Hazards model. Once we have a baseline model fit and the assumptions met, we can add our treatment variable to see how this affects the

	Chemo	
	AC	MI
cape/other/none	<.0001	<.0001
cape/other	0.0321	0.033
cape/none	0.00039	.0016
other/none	<.0001	<.0001

Table 3.5 : Chemo log rank tests

	HER2	
	AC	MI
Lapat/Traztuz/none	<.0001	<.0001
Lapat/Trastuz	.87	.81
Lapta/none	.00017	.00018
Trastuz/none	<.0001	<.0001

Table 3.6 : HER2 log rank tests

hazard. We first need to fit a reasonable model on the available cases. Speaking with the clinicians, they determined that the covariates listed in table 3.2 were clinically relevant for the baseline model.

We need to make sure that the proportional hazards assumption is met in the available case model to determine if the use of the Cox model is justified. To check, we visually inspect the spline fit to the Schoenfeld residuals over time. The available cases can be seen in figure 3.6. In the available cases, the assumption of proportional hazards over time seems reasonable, as it a straight line could reasonably be fit between the 95% confidence bands.




Figure 3.6 : AC Schoenfeld residuals over time

Now, to check if we have proportional hazards in the MI data, there are two options. The first is to fit a Cox model on the stacked data, but this will not give us accurate confidence bands. A better option is to collect all of the spline fits, and then superimpose them onto one plot, and assess the shape. This is what is done for the MI data, as can be seen in figure 3.7. The shapes are very similar to the available cases, so it is reasonable to assume that the proportional hazards assumption holds on the MI data.

Now that the assumptions are met, we can run the Cox model to obtain the hazard ratios. A table of the AC and MI analyses can be seen in table 3.7.

			AC n= 845			MI	
Variable	Contrast	HR	95% CI	pvalue		HR	95% CI pvalue (t test)
HR/HER2	-/+ vs. -/-	0.57	(0.46,0.71)	<0.0001		0.59	(0.48,0.72) <0.0001
	+/- vs. -/-	0.66	(0.54,0.81)	<0.0001		0.63	(0.52,0.76) <0.0001
	+/+ vs. -/-	0.4	(0.31,0.50)	<0.0001		0.4	(0.32,0.50) <0.0001
Age	>60 vs. <60	1.37	(1.13,1.65)	0.0011		1.45	(1.22,1.72) <0.0001
Dx to BM	>6 vs. <6	0.66	(0.54,0.82)	0.00013		0.71	(0.59,0.86) 0.0002
First DM	Brain vs. Oth	0.8	(0.66,0.97)	0.026		0.83	(0.70,0.99) 0.02
Race	Hisp. Vs. White	0.85	(0.68,1.07)	0.17		0.88	(0.71,1.08) 0.11
	Black vs. White	1.31	(1.06,1.63)	0.014		1.25	(1.02,1.52) 0.015
	Other vs. White	0.65	(0.40,1.04)	0.075		0.7	(0.45,1.07) 0.05
# prior Rx	>2 vs. 0-2	1.58	(1.31,1.91)	<0.0001		1.53	(1.29,1.82) <0.0001
BM type	Mult. Vs. Single	1.45	(1.20,1.76)	<0.0001		1.48	(1.24,1.76) <0.0001
	LMD vs. Single	1.6	(1.21,2.13)	0.001		1.58	(1.25,2.00) <0.0001
Sys. Cont.	Yes vs. No	0.71	(0.61,0.83)	<0.0001		0.73	(0.63,0.85) <0.0001

Table 3.7 : AC and MI baseline Cox model




Figure 3.7 : MI Schoenfeld residuals over time

We may then add in our treatment variable to see how it affects the hazard, and see how it changes other factors. Adding chemotherapy can be seen in 3.8, and for the HER2 positive patients, the HER2 directed drugs can be seen in 3.9. As it has been posited before, the use of chemo and HER2 drugs seem to greatly reduce the hazard ratio of death from cancer. The effect of other covariates in the presence of these drugs seems to change though.

3.4 Causal Analysis

This is the section that needs much more work. I'll only lay the outline here.

Lastly, we will want to draw causal inference, and see what the average treatment effect of each drug is. This is necessary because the data was collected from a database, and we did not have an RCT. As well, this piece of information is what clin-

			AC n=745			MI		
Variable	Contrast	HR	95% CI	p-value		HR	95% CI	p-value (t test)
HR/HER2	-/+ vs. -/-	0.62	(0.49,0.79)	<.0001		0.63	(0.51,0.77)	<.0001
	+/- vs. -/-	0.65	(0.53,0.81)	0.00011		0.64	(0.53,0.78)	<.0001
	+/+ vs. -/-	0.41	(0.31,0.53)	<.0001		0.42	(0.34,0.53)	<.0001
Age	>60 vs. <60	1.34	(1.10,1.64)	0.0041		1.44	(1.21,1.72)	<.0001
Dx to BM	>6 vs. <6	0.72	(0.58,0.90)	0.0032		0.71	(0.58,0.86)	0.00039
First DM	Brain vs. Oth	0.77	(0.63,0.95)	0.014		0.81	(0.68,0.96)	0.016
Race	Hisp. Vs. White	0.77	(0.61,0.98)	0.034		0.86	(0.69,1.06)	0.15
	Black vs. White	1.29	(1.02,1.63)	0.032		1.23	(1.01,1.51)	0.043
	Other vs. White	0.76	(0.47,1.25)	0.28		0.7	(0.45,1.08)	0.11
# prior Rx	>2 vs. 0-2	1.61	(1.32,1.98)	<.0001		1.53	(1.28,1.82)	<.0001
BM type	Mult. Vs. Single	1.46	(1.20,1.78)	0.00017		1.51	(1.27,1.81)	<.0001
	LMD vs. Single	1.45	(1.04,2.03)	0.029		1.41	(1.11,1.80)	0.0049
Sys. Cont.	Yes vs. No	0.57	(0.48,0.68)	<.0001		0.69	(0.59,0.80)	<.0001
Chemo	Cape. vs. none	0.69	(0.53,0.89)	0.0046		0.75	(0.60,0.95)	0.018
	other vs. none	0.52	(0.42,0.65)	<.0001		0.58	(0.47,0.71)	<.0001

Table 3.8 : AC and MI Cox model with chemo treatment

			AC n=292			MI	
Variable	Contrast	HR	95% CI	p-value		HR	95% CI p-value (t test)
HR/HER2	+/+ vs. -/+	0.65	(0.49,0.87)	0.0036		0.66	(0.51,0.85) 0.0015
Age	>60 vs. <60	1.38	(0.95,2.01)	0.092		1.58	(1.15,2.18) 0.0054
Dx to BM	>6 vs. <6	0.64	(0.43,0.97)	0.033		0.69	(0.49,0.99) 0.041
First DM	Brain vs. Oth	0.84	(0.58,1.20)	0.34		0.86	(0.62,1.17) 0.34
Race	Hisp. Vs. White	0.69	(0.46,1.02)	0.064		0.76	(0.53,1.09) 0.14
	Black vs. White	1.41	(0.94,2.11)	0.1		1.43	(1.00,2.04) 0.047
	Other vs. White	0.7	(0.32,1.53)	0.38		0.83	(0.46,1.52) 0.55
# prior Rx	>2 vs. 0-2	1.88	(1.34,2.63)	0.00028		1.71	(1.28,2.28) 0.00028
BM type	Mult. Vs. Single	1.3	(0.92,1.86)	0.14		1.25	(0.91,1.70) 0.16
	LMD vs. Single	2.15	(1.20,3.88)	0.011		1.77	(1.10,2.83) 0.018
Sys. Cont.	Yes vs. No	0.73	(0.55,0.97)	0.029		0.78	(0.60,1.01) 0.063
HER2 therapy	Lapat vs. none	0.47	(0.32,0.69)	0.00015		0.52	(0.37,0.75) 0.00036
	Trastuz vs. none	0.45	(0.33,0.61)	<.0001		0.51	(0.38,0.68) <.0001

Table 3.9 : AC and MI Cox model with HER2 directed treatment, on HER2+ subjects

icians and laypeople really want it answers the question of which drug is better. There are many interesting questions that we may ask with this dataset, but here we will only focus on Lapatinib /Trastuzumab /no treatment and Capecitabine/other/none.

The idea for this part of the analysis is to use propensity score weighting to create a balanced sample, and to be able to treat it as if it was an RCT. Let's do this first on the available cases. To do this though, we need to get an actual propensity score. In talking with the cancer professionals on the project, it was determined that covariates X,Y,Z, were important pretreatment variables that needed to be controlled for. In the available case analysis, we see that the standardized bias is $\{this\}$. Now, we fit a logistic regression / multinomial logistic model on the treatment status, with the Q variables to get our propensity score. We can look at the $\{standardized\ bias\}$ before and after the weighting to ensure that we have controlled properly, and to see if we may go forward. Assuming that we have removed the confounding factors and now have two groups that we can treat like it was an RCT, we may now run our Cox model again, but weight by the IPTW. Once we have done this, we can $\{observe\ the\ results\ from\ the\ AC\ analysis\}$.

Now we need to apply this propensity score weighting to the MI data. We discussed before the within and across method, and remarked that we were confined to use the within method, since our treatment variable (lapat/cape) was itself imputed. So the plan will be to fit the Cox models with the inverse propensity score weights discussed in the AC analysis. We need to be sure that the IPTW weighting is still valid in the MI setting though, so we check $\{standard\ biased,\ other\ things\}$. Now we may then pool the results via Rubin's rules and analyze is through the Rubin causal model framework. $\{the\ results\ can\ be\ seen\ here\}$. The results that we can draw from this are X,Y,Z

Chapter 4

Discussion

We have discussed a number of tools and methods to analyze survival data with missingness and make causal inference. There are lots of decisions to be made along the way, and I am in no way advocating that my exact choices will be proper for all situations, I am only claiming that the decisions made were proper for the type of data and questions that we had. I hope that I have given the reader enough information to run their own analysis, even if they don't choose the options that I did.

There will certainly be many disagreements about the multiple imputation portion. And since the multiple imputation serves as the root of the analysis, the concerns should be addressed. The first concern comes from people who don't understand or believe in imputation of missing values. Multiple imputation is a tool to help us find plausible values for missing data. We will make no claim that the imputed values are right, but when used correctly, the results from subsequent analyses will be unbiased. We aren't using multiple imputation to create data where there is none, rather we are using it to "fill gaps" in places that we already do have data. We actually need to impute in certain cases if we want to get valid results, as analysis without imputation will lead to severely biased results [1]. The next and more substantial critique will come from statisticians who may not believe that the distribution that the imputations is being drawn from is valid. Multiple imputation is inherently a parametric procedure. No matter what method we use to impute, we have to make a parametric assumption, be it the joint model for JM or the full conditionals for

FCS. For our case, using the normal model is certainly wrong because we have so many categorical and strictly positive variables (which is proven to be suboptimal in [16]), so we are left only with using FCS. And FCS alone has weak theoretical justification. But as we have discussed before, many studies have shown that FCS is robust to non-compatibility. As well, there was no formal model validation (such as cross validation), only ad hoc checks. In the literature there is hardly any mention of validation, because if we were to cross validate, we would be drawing from different models, and comparison between the folds would be like comparing apples to oranges. We already have missing data, there is no reason to destabilize it to try to compare it, as the standard methods seem to work fine [1].

An interesting future extension to this project would be to use a non parametric approach to multiple imputation, such as the one suggested by Long et al in [34]. But at the time of publication, there is not much literature or software on this subject, so I felt that it was not appropriate to use its results.

To summarize about multiple imputation, I would say that it is a necessary evil. In the process of using multiple imputation, we lose predictive power, and are forced to use a distribution that may not fit the data to a t. But we need to use imputation techniques if we want to make any sense of our data. The advice I would give to those who are hesitant to use multiple imputation would be to not have missing data, but this is a task that is easier said than done. Multiple imputation is becoming the standard for missing data techniques, especially in the medical field. There are lots of pros to it, but there are certainly some cons. Much research has already gone in to it, but much more needs to be done. It is my hope that this thesis has shown a powerful example of why multiple imputation should be used.

Next we can critique the survival section. We made a lot of assumptions about how

our subjects were censored. We assumed that all of our subjects who were censored were right censored and non-informative. This seems to be a valid assumption, but there certainly exists left truncation. It may have been the case that there were some left truncated subjects, but once we landmarked, we certainly incurred some left truncation.

We decided to use standard Kaplan-Meier and Cox analyses because they are very standard in practice, and answer the questions well. However, some other methods could have been used. A popular theoretical model is called the accelerated failure time model (AFT), which describes how covariates affect the survival time, assuming that it acts in a multiplicative fashion. This is useful analysis for clinicians and statisticians, but not really good for patients, because the conclusions drawn from it are “drug x will make you live 50

There are three concepts in survival analysis that I find interesting, but our data did not allow for it. The first is variable selection. The clinicians knew what they wanted to test, so this was not needed, but variable selection in the context of MI is an interesting question, and van Buuren covers it in his book [1]. This would be very useful if our dataset had covariates that we were unsure of their predictive power or wanted to examine. Another interesting addition would be using multistate data. In this setting, subjects can transfer from one group to another, i.e. have cancer, metastasize to the brain, get in to remission, and then relapse. We model the states as a stochastic process. This would be really interesting, and I would have liked to implement it because I think it would have been interesting from a multiple imputation perspective, but unfortunately our data was not conducive to that.

The last addition would be survival in the competing risks setting. I think that modeling death in the presence of other factors would be very interesting. Our data

structure supported this type of analysis, but it was not requested by the clinicians.

[This needs more work] Lastly, we move on to the causal analysis part. While there are many other binary classifiers that could be used to make propensity scores, we chose to use logistic regression. We chose to weight, using IPTW. We chose to model the propensity scores only on the variables that the clinicians thought were useful, and we did not do any variable selection. There is a possibility that we omitted an important discriminating variable. The choice of using logistic regression IPTW was based solely on tradition and ease of understanding from non-statisticians. I included a section about how we could use propensity scores to match, and while this is used by a lot of researchers, new statistical studies argue about its validity. The results we obtained through propensity are causal, but some people still may argue about its validity because we did not have a RCT.

Chapter 5

Conclusion

This paper details how to use multiply imputed data to answer survival and causal analysis questions. The motivation for the methods used is cancer data, although sufficient detail is given so that the methods can be applied towards other areas. The first section gives background information. In the second, we discuss the methods and theory used as well as alternative methods of use. In the third section, we test the methods out on a large cancer dataset, trying to draw meaningful inference from a dataset with substantial missingness. We model some basic survival quantities and draw causal inference from it.

Appendix A

Appendix

A.1 Missing data mechanisms

There are three mechanisms of missing data. It is important to understand what type of missing data we have so that we can use methods that are suited for that type. Before we begin, we will need some notation. It is not constant throughout the literature, so I caution you to look at the authors notation before reading any other literature. I will give the symbols I will be using along with words to describe them to make it easy to understand and explain.

- Y is our whole dataset. It will have i rows and j columns. Some of the covariates in the dataset will be completely observed, and others will have missingness.
- Y_j is a specific column of Y . Y_j is composed as $Y_j = (Y_{j,obs}, Y_{j,mis})$, where
 - $Y_{j,obs}$ is the data we have observed for covariate j
 - $Y_{j,mis}$ is the missing data covariate j
- Y_{obs} is all of the data that we have observed
- Y_{mis} is all the data that we have not observed
- R is a binary matrix the same size as Y where a 1 indicates we observed the data, and 0 means it is missing
- ψ is a vector of parameters for the missing data model.

- The missing data model is given as $p(R|Y_{obs}, Y_{mis}, \psi)$
- θ is a vector of the parameters for the full model of Y

As well, we have a concept called ignorability, which is defined as

$$p(Y_{mis}|Y_{obs}, R) = p(Y_{mis}|Y_{obs})$$

That is, we may “ignore” the R . The probability of the data being missing does not depend on how the data is missing. Equivalently, we may write this as

$$p(Y_{mis}|Y_{obs}, R = 1) = p(Y_{mis}|Y_{obs}, R = 0)$$

Being ignorable makes it justified to model our missing data from our observed data, without needing to worry about how it was missing. The opposite of ignorable data is called non-ignorable data, in this case,

$$p(Y_{mis}|Y_{obs}, R = 1) \neq p(Y_{mis}|Y_{obs}, R = 0)$$

So we must take into account the missing data structure for imputation. We often times see ignorable missing data in practice, although one should certainly check the sensibility of ignorability, as some instances will certainly be non-ignorable, for example censored data, or when we know that the missing data is systematically different than the observed. If we have strongly nonignorable data, we should either try one of two things. The first is to expand the data (collect something else similar to the covariate with missingness) so that it becomes ignorable and the second is to formulate two imputation models, one for the observed and one for the missing.

Now, we may discuss the three main types of missing data mechanisms. I will give the technical definition, a laymans definition, and an example.

- MCAR: Missing completely at random: $P(R = 0|Y_{obs}, Y_{mis}, \psi) = P(R = 0|\psi)$.
The missingness in the data is not at all related to any of the data that we do or don't have. If a lab technician slips and drops 5 vials of blood, the missingness caused by this would be MCAR
- MAR: Missing at random: $p(R = 0|Y_{obs}, Y_{mis}, \psi) = p(R = 0|Y_{obs}, \psi)$. The missingness we have is related to something in the data. If we collect the gender of the subject and we know that males tend to not give blood, we can attribute the missingness to the gender. In general, MAR models are ignorable [1].
- MNAR: Missing not at random: $p(R = 0|Y_{obs}, Y_{mis}, \psi)$ does not simplify, and the missingness depends on data that we have as well as have not collected. For example if a full moon causes the blood testing machine to break more often, but we don't have the moon phase as a variable.

A.2 Cancer and Treatment Overview

Cancer is a disease in humans where cells in the body begin to grow in an uncontrolled manner [35]. There are many different types of cancers for the many different types of tissues we have. This paper focuses on breast cancer.

Breast cancer is a common type of cancer with many different subclassifications, that affects both men and women, although women much more [35]. It can be inherited, but often can be detected early on with screening and self-examination. Most cases of breast cancer are sporadic, but studies have shown that a woman's risk to get breast cancer is doubled if a first degree relative has breast cancer (i.e. it is genetic). When breast cancer is inherited, it often presents itself earlier in life [36]. One of the major risks of breast cancer is that it will metastasize, that is, the cancerous cells move from the breast to another area of the body. It should be noted that when a cancer metastasizes to another part of the body, the patient is said to have the original cancer metastasized to a new area, not a new cancer. For example, in this paper we study breast cancer patients who have metastases to the brain, not brain cancer patients. The reason for this is because the makeup of the cancer cell is the same type of tissue as the original location, not the new one.

Luckily, there are lots of different types of treatments for breast cancer and its metastases. I will list the major types here.

- Chemotherapy is a class of drugs given to cancer patients. These types of drugs target fast growing cells (like cancer) and kill them. Capecitabine is a common chemotherapeutic drug
- HER2 directed therapy: HER2 is a human protein that is associated with cell growth. If it is determined that the patient has the HER2 protein, then HER2

directed therapies can be used. In HER2 directed therapies, a drug is given that targets the HER2 protein and tries to stop its effect . Common HER2 directed therapies include Lapatinib and Trastuzumab, which we discuss in this paper.

- Radiation therapy: When the cancer tumor is radiated by precisely located beams in hopes of killing or disturbing the cancer growth process by destroying the cancer DNA.
- Surgery: A doctor goes in and physically removes the cancerous cells.
- Hormone therapy: Some cancers have hormone receptors in the tumor cells. If this is the case, then drugs that interfere with these receptors can be used

Often times, a combination of these treatments is used. The exact course of treatment is very dependent on the type of cancer and the type of person. For example, chemotherapy is very difficult on the body, so it is not often used on the very elderly and frail. The course of treatment given should be determined by a subject matter expert (the oncologist), and is highly individual and cancer dependent. There have been many books and articles written about these, and for more information, you can check out [35] and [36].

Bibliography

- [1] S. van Buuren, *Flexible imputation of missing data*. 2012.
- [2] D. Rubin, *Multiple Imputation for Nonresponse in Surveys*. No. JOHN WILEY & SONS, 1987.
- [3] J. Klein and M. Moeschberger, *Techniques for Censored and Truncated Data*. 1984.
- [4] E. L. Kaplan and P. Meier, “Nonparametric Estimation from Incomplete Observations,” *Journal of the American Statistical Association*, vol. 53, no. 282, pp. 457–481, 1958.
- [5] J. M. Bland and D. G. Altman, “The logrank test.,” *BMJ (Clinical research ed.)*, vol. 328, no. 7447, p. 1073, 2004.
- [6] D. Cox, “Regression Models and Life-Tables,” *Journal of the Royal Statistical Society. Series B (Methodological)*, vol. 34, no. 2, pp. 187–220, 1972.
- [7] T. H. H. S. Library, “Study Design 101,” 2011.
- [8] S. Guo and M. W. Fraser, “Propensity score analysis. Statistical methods and application,” 2010.
- [9] P. Rosenbaum and D. Rubin, “The Central Role of the Propensity Score in Observational Studies for Causal Effects,” vol. 70, no. 1, pp. 41–55, 1983.

- [10] G. King and R. Nielsen, “Why Propensity Scores Should Not Be Used for Matching,” *Working paper*, 2015.
- [11] J. Angrist and J. Pischke, *Mostly harmless econometrics: An empiricist’s companion*. No. March, 2008.
- [12] J. K. Lunceford and M. Davidian, “Stratification and weighting via the propensity score in estimation of causal treatment effects: A comparative study,” *Statistics in Medicine*, vol. 23, no. 19, pp. 2937–2960, 2004.
- [13] D. F. Griffin, Beth Ann McCaffrey, “TWANG Short Course.”
- [14] P. C. Austin, “The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments,” *Statistics in Medicine*, vol. 33, no. 7, pp. 1242–1258, 2014.
- [15] H. Demirtas and D. Hedeker, “Imputing continuous data under some non-Gaussian distributions,” *Statistica Neerlandica*, vol. 62, no. 2, pp. 193–205, 2008.
- [16] J. Kropko, B. Goodrich, A. Gelman, and J. Hill, “Multiple Imputation for Continuous and Categorical Data: Comparing Joint Multivariate Normal and Conditional Approaches,” *Political Analysis*, pp. 497–519, 2014.
- [17] J. Honaker, G. King, and M. Blackwell, “AMELIA II : A Program for Missing Data,” *Journal Of Statistical Software*, vol. 45, no. 7, pp. 1–54, 2011.
- [18] A. A. Novo and J. L. Schafer, “Package `norm`,” *CRAN*, 2015.
- [19] F. Tusell, “Package `cat`,” *CRAN*, p. 23, 2015.

- [20] S. Van Buuren and K. Groothuis-Oudshoorn, “mice: Multivariate Imputation by Chained Equations in R,” *Journal Of Statistical Software*, vol. 45, no. 3, pp. 1–67, 2011.
- [21] S. Van Buuren, J. P. Brand, C. G. Groothuis-Oudshoorn, and D. Rubin, “Fully conditional specification in multivariate imputation,” *Journal of Statistical Computation and Simulation*, vol. 76, no. 12, pp. 1049–1064, 2006.
- [22] Y.-S. Su, A. Gelman, J. Hill, and M. Yajima, “Multiple Imputation with Diagnostics (mi) in R: Opening Windows into the Black Box,” *Journal of Statistical Software*, vol. 45, no. 2, pp. 1–31, 2011.
- [23] A. Florian and M. F. Meinfelder, “BaBooN: Bayesian Bootstrap Predictive Mean Matching - Multiple and Single Imputation for Discrete Data,” 2015.
- [24] C. K. Enders, *Applied Missing Data Analysis*. 2010.
- [25] Y. Zhao, A. H. Herring, H. Zhou, M. W. Ali, and G. G. Koch, “ANALYSES OF TIME-TO-EVENT DATA WITH POSSIBLY,” vol. 24, no. 2, pp. 229–253, 2014.
- [26] A. Gelman and D. Rubin, “Inference from iterative simulation using multiple sequences,” *Statistical Science*, vol. 7, no. 4, pp. 457–511, 1992.
- [27] J. Barnard and D. Rubin, “Small-sample degrees of freedom with multiple imputation,” *Biometrika*, vol. 86, no. 4, pp. 948–955, 1999.
- [28] A. Marshall, D. G. Altman, R. L. Holder, and P. Royston, “Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines,” *BMC medical research methodology*, vol. 9, p. 57, 2009.

- [29] D. Schoenfeld, “Partial Residuals for the Proportional Hazards Regression-Model,” *Biometrika*, vol. 69, no. 1, pp. 239–241, 1982.
- [30] R. Mitra and J. P. Reiter, “A comparison of two methods of estimating propensity scores after multiple imputation,” *Statistical Methods in Medical Research*, pp. 1–17, 2012.
- [31] D. F. McCaffrey, B. A. Griffin, D. Almirall, M. E. Slaughter, R. Ramchand, and L. F. Burgette, “A tutorial on propensity score estimation for multiple treatments using generalized boosted models,” *Statistics in Medicine*, vol. 32, no. 19, pp. 3388–3414, 2013.
- [32] J. P. Reiter, “Selecting the number of imputed datasets when using multiple imputation for missing data and disclosure limitation,” *Statistics & Probability Letters*, vol. 78, no. 1, pp. 15–20, 2008.
- [33] I. White, P. Royston, and A. M. Wood, “Multiple imputation using chained equations: Issues and guidance for practice,” *Statistics in Medicine*, vol. 30, no. 4, pp. 377–399, 2011.
- [34] Q. Long, C.-H. Hsu, and Y. Li, “Doubly robust nonparametric multiple imputation for ignorable missing data,” *Statistica Sinica*, vol. 22, no. 1, pp. 1–22, 2012.
- [35] G. Cooper, *Elements of Human Cancer*. Boston: Jones and Bartlett Learning, 1992.
- [36] D. Morris, J. Kearsley, and C. Williams, *Cancer: A Comprehensive Clinical Guide*. 1998.